Implication of Transcriptional Repression in Compound C-induced Apoptosis in Cancer Cells
R Y Dai,X F Zhao,J,R Chen,Z L Luo,L X Yu,S K Chen,C Y Zhang,C Y Duan,Y P Liu,C H Feng,X M Xia,H Li,J Fu,H Y Wang
DOI: https://doi.org/10.1038/cddis.2013.419
2013-01-01
Cell Death and Disease
Abstract:Compound C, a well-known inhibitor of AMP-activated protein kinase (AMPK), has been reported to induce apoptosis in some types of cells. However, the underlying mechanisms remain largely unclear. Using a DNA microarray analysis, we found that the expression of many genes was downregulated upon treatment with compound C. Importantly, compound C caused transcriptional repression with the induction of p53, a well-known marker of transcriptional stress response, in several cancer cell lines. Compound C did not induce the phosphorylation of p53 but dramatically increased the protein level of p53 similar to some other transcriptional inhibitors, including 5,6-dichloro-1- β - D -ribobenzimidazole (DRB). Consistent with previous reports, we found that compound C initiated apoptotic death of cancer cells in an AMPK-independent manner. Similar to DRB and actinomycin D (ActD), two classic transcription inhibitors, compound C not only resulted in the loss of Bcl-2 and Bcl-xl protein but also induced the phosphorylation of eukaryotic initiation factor-alpha (eIF2 α ) on Ser51. Hence, the phosphorylation of eIF2 α might be a novel marker of transcriptional inhibition. It is noteworthy that compound C-mediated apoptosis of cancer cells is correlated with decreased expression of Bcl-2 and Bcl-xl and the phosphorylation of eIF2 α on Ser51. Remarkably, compound C exhibits potent anticancer activities in vivo . Taken together, our data suggest that compound C may be an attractive candidate for anticancer drug development.